Strategy Capital LLC Sells 44,835 Shares of Axon Enterprise, Inc $AXON

Strategy Capital LLC cut its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 10.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 386,742 shares of the biotechnology company’s stock after selling 44,835 shares during the quarter. Axon Enterprise accounts for about 16.2% of Strategy Capital LLC’s portfolio, making the stock its 2nd biggest position. Strategy Capital LLC’s holdings in Axon Enterprise were worth $219,642,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. NEOS Investment Management LLC grew its stake in shares of Axon Enterprise by 82.7% in the third quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after buying an additional 11,482 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Axon Enterprise by 1.3% in the fourth quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after buying an additional 5,419 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after buying an additional 376,904 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of Axon Enterprise in the fourth quarter valued at $13,116,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Axon Enterprise by 93.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock valued at $13,270,000 after buying an additional 11,262 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. UBS Group decreased their target price on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. The Goldman Sachs Group set a $535.00 target price on shares of Axon Enterprise in a research note on Thursday, May 7th. Citizens Jmp decreased their target price on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a research note on Thursday, May 7th. Wall Street Zen raised shares of Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Piper Sandler decreased their target price on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Insider Activity

In other Axon Enterprise news, President Joshua Isner sold 13,000 shares of Axon Enterprise stock in a transaction on Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the transaction, the president directly owned 169,125 shares of the company’s stock, valued at $82,609,106.25. The trade was a 7.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of Axon Enterprise stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 39,344 shares of company stock valued at $19,267,315. 4.20% of the stock is owned by company insiders.

Axon Enterprise Trading Down 1.0%

AXON stock opened at $441.73 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The company has a fifty day moving average price of $410.34 and a two-hundred day moving average price of $489.19. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91. The stock has a market cap of $35.60 billion, a price-to-earnings ratio of 177.40, a price-to-earnings-growth ratio of 8.11 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million during the quarter, compared to analysts’ expectations of $778.91 million. During the same period in the previous year, the business posted $1.47 earnings per share. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. Equities analysts anticipate that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.